Your browser doesn't support javascript.
loading
Comparison of Sugammadex versus Neostigmine Costs and Respiratory Complications in Patients with Obstructive Sleep Apnoea.
Ünal, Dilek Yazicioglu; Baran, Ilkay; Mutlu, Murad; Ural, Gülçin; Akkaya, Taylan; Özlü, Onur.
Afiliação
  • Ünal DY; Clinic of Anaesthesiology and Reanimation, Ministry Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Baran I; Clinic of Anaesthesiology and Reanimation, Ministry Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Mutlu M; Clinic of Otorhinolaryngology, Ministry Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Ural G; Clinic of Anaesthesiology and Reanimation, Ministry Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Akkaya T; Clinic of Anaesthesiology and Reanimation, Ministry Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Özlü O; Clinic of Anaesthesiology and Reanimation, Ministry Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Turk J Anaesthesiol Reanim ; 43(6): 387-95, 2015 Dec.
Article em En | MEDLINE | ID: mdl-27366535
ABSTRACT

OBJECTIVE:

To compare sugammadex and neostigmine regarding the efficacy in reversing rocuronium-induced neuromuscular block, the incidence of post-operative respiratory complications and costs in patients undergoing surgery for the treatment of obstructive sleep apnoea (OSA).

METHODS:

After obtaining ethical approval and patient consent, 74 patients in ASA physical status I or II were randomised into two groups to receive 2-mg kg(-1) sugammadex (Group S) or 0.04-mg kg(-1) neostigmine+0.5-mg atropine (Group N). Groups were compared regarding time to TOF (train-of-four) 0.9, operating room time, post-anaesthesia care unit (PACU) stay, post-operative respiratory complications, costs related to neuromuscular block reversal, anaesthesia care and complication treatment.

RESULTS:

Patient demographics, anaesthesia, surgical data and total rocuronium doses were similar between groups. Time to TOF 0.9 was shorter for group S [Group N 8 (5-18) min; Group S 2 (1.5-6) min (p<0.001)]. Operating room time [Group S 72.4±14.3 min; Group N 96.6±22.8 min (p<0.001)] and PACU stay [Group S 22.9±10.1 dk; Group N 36.3±12.6 dk (p<0.001)] were also shorter in Group S. After extubation, desaturation was observed in 12 (32.4%) patients in group N and in 4 (8%) patients in group S (p=0.048). In group N, three patients were reintubated; there were eight (21.6%) unplanned intensive care unit (ICU) admissions. There was one unplanned ICU admission in group S. Negative pressure pulmonary oedema was observed in one patient in group N. The results regarding costs were as follows. The reversal cost was higher in the sugammadex group (vial cost 98.14 TL) than that in the neostigmine group (ampoule cost 0.27 TL; total 6147.88 TL vs. 3569.5 TL); however, complication treatment cost and total cost were lower in group S than those in group N (199.5 TL vs. 3944.6 TL) (staff anaesthesia doctor cost was 0.392 TL per min and the cost of nurse anaesthetist was 0.244 TL per min).

CONCLUSION:

This study confirmed the efficacy of sugammadex over neostigmine for the reversal of rocuronium-induced neuromuscular block. Sugammadex decreases the incidence of post-operative respiratory complications and related costs in patients with OSA.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation Idioma: En Revista: Turk J Anaesthesiol Reanim Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation Idioma: En Revista: Turk J Anaesthesiol Reanim Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Turquia